Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose Furmonertinib Versus Osimertinib as First-line Treatment in Advanced EGFR Mutation-positive NSCLC Patients With Brain Metastases: a Multi-center, Randomized, Controlled, Prospective, Phase II Clinical Trial

NCT06319950 is registered in ClinicalTrials.gov with Taizhou Hospital as lead sponsor.

NCT NCT06319950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06319950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose Furmonertinib Versus Osimertinib as First-line Treatment in Advanced EGFR Mutation-positive NSCLC Patients With Brain Metastases: a Multi-center, Randomized, Controlled, Prospective, Phase II Clinical Trial
Lead sponsor
Taizhou Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2024
Completion date
December 30, 2026
Enrollment
255 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, nonsmall cell